Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,461 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement.
Jakobsen P, Bastholt L, Dalmark M, Pfeiffer P, Petersen D, Gjedde SB, Sandberg E, Rose C, Nielsen OS, Mouridsen HT. Jakobsen P, et al. Among authors: rose c. Cancer Chemother Pharmacol. 1991;28(6):465-9. doi: 10.1007/BF00685824. Cancer Chemother Pharmacol. 1991. PMID: 1934250 Clinical Trial.
Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.
Bastholt L, Dalmark M, Gjedde SB, Pfeiffer P, Pedersen D, Sandberg E, Kjaer M, Mouridsen HT, Rose C, Nielsen OS, Jakobsen P, Bentzen SM. Bastholt L, et al. Among authors: rose c. J Clin Oncol. 1996 Apr;14(4):1146-55. doi: 10.1200/JCO.1996.14.4.1146. J Clin Oncol. 1996. PMID: 8648369 Clinical Trial.
Concurrent tamoxifen (TAM) + cyclophosphamide, epirubicin, and fluorouracil (CEF) versus TAM + delayed CEF after six months of endocrine therapy in metastatic breast cancer--a randomized trial from the Danish Breast Cancer Cooperative Group (DBCG).
Pfeiffer P, Rose C, Ejlertsen B, Andersson M, Pedersen D, Mouridsen HT. Pfeiffer P, et al. Among authors: rose c. Acta Oncol. 1996;35 Suppl 5:57. doi: 10.3109/02841869609083970. Acta Oncol. 1996. PMID: 9142967 Clinical Trial. No abstract available.
Challenges in the endocrine management of breast cancer.
Mouridsen HT, Rose C, Brodie AH, Smith IE. Mouridsen HT, et al. Among authors: rose c. Breast. 2003 Aug;12 Suppl 2:S2-19. doi: 10.1016/s0960-9776(03)80158-3. Breast. 2003. PMID: 14659138 Review.
Endocrine therapy of advanced breast cancer.
Rose C, Mouridsen HT. Rose C, et al. Acta Oncol. 1988;27(6A):721-8. doi: 10.3109/02841868809091775. Acta Oncol. 1988. PMID: 3064777 Clinical Trial.
2,461 results